Advertisement

Topics

Latest Biological Therapy NewsRSS

13:08 EDT 25th June 2017 | BioPortfolio

UK Cancer Diagnostics Market Analysis 2021: Supplier Shares and Strategies, Emerging Tumor Markers, Volume and Sales Segment Forecasts, Technology and Instrumentation [Updated: 01011970] Prices from USD $6800

Complete report $6,800. DataPack test volumes, sales forecasts, supplier shares $4,350.VPGMarketResearchrsquo;s new reportis a study of the major business opportunities emerging in the UK cancer diagnostics market during the next five years. The report examines trends in the UK cancer diagnostics markets, reviews current and emerging assays; analyzes potential applications of new diagnostic techno...

Scientists “Turn Off” Tumor-Protecting Protein in New Mesothelioma Study, According to Surviving Mesothelioma

New research suggests that microRNAs may be the key to downregulating PD-L1 and improving immunotherapy treatment for malignant mesothelioma. Raleigh, NC (PRWEB) June 25, 2017 Australian researchers studying the protein PD-L1 have developed a way to potentially turn off the mechanism that lets mesothelioma tumors hide from the immune system. Surviving Mesothelioma has the full story. Click here t...

Leica Biosystems Introduces New Novocastra HD Antibody Menu for Head and Neck Pathology

NEWCASTLE UPON TYNE, England, January 8, 2013 /PRNewswire/ -- The Novocastra™ HD menu for head and neck pathology comprises six antibodies[#], each selected following extensive customer research and independent evaluation* by external QA.  The menu is the second portfolio of antibodies to launch from the new Novocastra HD range, following on from the introduction of the Novocastra HD m...

Toward the stars: On humility and pain in medicine

Your brain is a three-pound hunk of biological tissue. And though it’s nothing more than a conglomeration of specialized cells, it generates the taste of cheesecake, the ecstasy of enchantment, and the misery of suffering. Amazing, right? I certainly think so, though I find myself among a shrinking minority. Whereas the eyes of our medical […]

OriGene Publishes Landmark Paper on Revolutionary Proteome Platform for Antibody Specificity Test

ROCKVILLE, Md., Jan. 7, 2013 /PRNewswire/ -- OriGene Technologies, Inc. ("OriGene"), one of the industry leaders in producing genome wide products for research and diagnostic applications, has brought the antibody field one step closer to identifying and developing ultra-specific monoclonal antibodies.  Specificity of antibodies for research or clinical applications is of cri...

Cantel Medical To Present At 15th Annual Needham Growth Conference

LITTLE FALLS, N.J., Jan. 7, 2013 /PRNewswire/ -- CANTEL MEDICAL CORP. (NYSE: CMN) announced today that Andrew A. Krakauer, President & CEO, will be presenting at the Needham 15th Annual Growth Conference. The formal presentation is scheduled for 2:50 PM ET on Thursday, January 17, 2013 at The New York Palace Hotel, with a Q & A session immediately following the presentation. In additi...

Vaccinex, Inc. Announces Initiation of a Phase 1 Clinical Trial of VX15/2503 Antibody in Multiple Sclerosis Patients

ROCHESTER, N.Y., Jan. 7, 2013 /PRNewswire/ -- Vaccinex, Inc. announced today that it has initiated a Phase 1 clinical trial to assess the safety, tolerability and pharmacokinetics of therapeutic antibody candidate VX15/2503 in patients with multiple sclerosis. VX15/2503 is a novel humanized monoclonal antibody targeting the multi-functional protein semaphorin 4D (SEMA4D), and represents the secon...

Lyme Disease Testing Market 2021: US, Europe, JapanSupplier Shares, Sales Forecasts, Innovative Technologies, Competitive Strategies, Emerging Opportunities [Updated: 13062017] Prices from USD $4350

The report presents a detailed analysis of the Lyme disease diagnostics market in the US, Europe France, Germany, Italy, Spain, UK and Japan. Current scientific views on the Lyme disease definition, epidemiology and etiology are reviewed. The report provides the 5year test volume and sales forecasts by country for the following market segments:nbsp; nbsp; nbsp; Hospitalsnbsp; nbsp; nbsp; Commerc...

Epizyme, Eisai and Roche to Develop EZH2 Companion Diagnostic

CAMBRIDGE, Mass., Jan. 7, 2013 /PRNewswire/ -- Epizyme, Inc., a biopharmaceutical company leading the creation of personalized therapeutics to treat patients with genetically defined cancers, Eisai Co., Ltd. (ESALY) and Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today a collaboration to develop an in vitro PCR (Polymerase Chain Reaction) based companion diagnostic test. The collaboration's goal ...

Ambrx Appoints Lawson Macartney, Ph.D., DVM, Chief Executive Officer

SAN DIEGO, Jan. 7, 2013 /PRNewswire/ --  Ambrx today announced the appointment of Lawson Macartney, Ph.D., DVM, to president and chief executive officer of the company and a member of the board of directors. Macartney brings more than 20 years of experience in the pharmaceutical industry, including recent work growing and diversifying the clinical pipeline of Shire Pharmaceuticals as senior v...

Sanofi's Chattem Acquires Over-the-Counter Antacid Rolaids®

PARIS, Jan. 7, 2013 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE : SNY) today announced that its US Consumer Healthcare Division, Chattem, Inc., completed the acquisition of the worldwide rights to the Rolaids® brand from McNeil Consumer Healthcare Division of McNEIL-PPC, Inc. "The addition of Rolaids represents a rare opportunity to obtain an iconic brand that we believe wi...

Synthetic Biologics to Present at OneMedForum San Francisco 2013

ROCKVILLE, Md., Jan. 7, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious infections and diseases, announced today that Jeffrey Riley, CEO, will present at the Sixth Annual OneMedForum San Francisco 2013 on Wednesday, January 9, 2013 at 9:20 a.m. (PT)/12:20 p.m. (ET). The conference will be held January 7-9,...

Pepscan Therapeutics Signs Multi-Target Agreement for Antibody Discovery

LELYSTAD, the Netherlands, January 7, 2013 /PRNewswire/ -- Pepscan Therapeutics, a world leader in protein mimicry technologies for raising anti-GPCR antibodies, today announced a multi-target research agreement with an undisclosed US-based antibody discovery company. Under the agreement Pepscan using its CLIPS platform and other protein mimicry technologies will work with the partner in the...

arGEN-X Expands its Therapeutic Antibody Alliance With Shire

BREDA, the Netherlands, January 7, 2013 /PRNewswire/ -- New Discovery Program Initiated Within 12 Months Of Collaboration Start arGEN-X, a biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody products, is broadening its therapeutic antibody collaboration with Shire. Initiated in March 2012, the existing alliance is focused on a...

PATH Malaria Vaccine Initiative and Inovio Pharmaceuticals Partner to Accelerate Development of Malaria Vaccines and Innovative Delivery Technologies

WASHINGTON and BLUE BELL, Pa., Jan. 7, 2013 /PRNewswire/ -- The PATH Malaria Vaccine Initiative (MVI) and Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced a follow-on collaboration to advance malaria vaccine development and new vaccination delivery technologies. Researchers will test whether a novel vaccine approach that combines genetically engineered DNA with an innovative vaccine de...

Department of Health Offers Free Flu Vaccinations at 2013 PA Farm Show

HARRISBURG, Pa., Jan. 4, 2013 /PRNewswire-USNewswire/ -- The Department of Health will offer free influenza vaccines at the 2013 Pennsylvania Farm Show, Jan. 5-11 from 8:30 a.m. to 4 p.m. and Jan. 12 from 8:30 a.m. to 2:30 p.m. To date, influenza cases have been reported in all Pennsylvania counties with a number of nursing homes experiencing outbreaks. "While the flu made an early appearance t...

GlycoVaxyn AG Signs Exclusive License Agreement and Enters Research and Development Collaboration with Janssen Pharmaceuticals, Inc., to Develop Multi-Valent Bacterial Vaccine

ZURICH-SCHLIEREN, Switzerland, Jan. 4, 2013 /PRNewswire/ -- GlycoVaxyn AG, a leader in the development of innovative vaccines, today announced that Janssen Pharmaceuticals, Inc. (JPI), has signed an exclusive license agreement and entered into a three-year research and development collaboration to develop a multi-valent bacterial vaccine employing GlycoVaxyn's bio-conjugation technology. "Ba...

ArmaGen Technologies, Inc. Hires Biotech Executive as CEO

LOS ANGELES, Jan. 3, 2013 /PRNewswire/ -- ArmaGen Technologies, Inc., a leader in the delivery of biotherapeutics targeting the central nervous system (CNS), today announced James Callaway, Ph.D. as Chief Executive Office and member of the Board of Directors.  Dr. Callaway was most recently President and CEO of Cebix Inc. and joins ArmaGen with nearly 30 year of experience in biotechnology re...

Organization Makes Season of Giving a Reality for Many Veterans

WINCHESTER, Calif., Jan. 3, 2013 /PRNewswire/ -- For many, the 2012 holiday season may have been a rough time financially, with gift giving being a major part of holiday activities.  And unfortunately, many of our nation's veterans, whether hospitalized or homebound, often have a tough time coming up with the resources needed to provide meaningful gifts for their families. (Logo: http:/...

Actinium Pharmaceuticals, Inc. Goes Public via a Reverse Merger into Cactus Ventures, Inc.

NEW YORK, Jan. 3, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. ("Actinium") announced today that it went public via a reverse merger into Cactus Ventures, Inc. (OTCBB: CTVN), a fully reporting public company (the "Company") pursuant to a share exchange agreement dated December 28, 2012. As a result of the share exchange, former shareholders of Actinium became the controll...

Sutro Biopharma to Collaborate with Sanofi Pasteur on a Novel Production Approach for Vaccine Candidates

SAN FRANCISCO, Jan. 3, 2013 /PRNewswire/ -- Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics utilizing Sutro's cell-free protein synthesis technology, today announced a collaboration with Sanofi Pasteur -- the largest company entirely dedicated to vaccines -- to produce two undisclosed vaccine candidates. "This collaboration highlights the potential...

Revalesio's RNS60 Protects Myelin and Halts Multiple Sclerosis in Mice

TACOMA, Wash., Jan. 3, 2013 /PRNewswire/ -- Results from a collaborative project between Revalesio and Dr. Kalipada Pahan at Rush University showed remarkable therapeutic activity of Revalesio's novel therapeutic RNS60 in a mouse model of multiple sclerosis (MS).  In a study recently published in the journal PLOS ONE, RNS60 halted disease progression (as measured by progressive limb para...

TNI BioTech to Present at 6th Annual OneMedForum San Francisco 2013

NEW YORK and POTOMAC, Md., Jan. 3, 2013 /PRNewswire/ -- TNI BioTech, Inc. (PINKSHEETS: TNIB), a public company operating in the biotech sector, today announced that Noreen McGurrin Griffin, Chief Executive Officer, and Dr. Ronald Herberman, Chief Medical Officer, are scheduled to speak at the 6th Annual OneMedForum at the Sir Frances Drake Hotel, San Francisco, CA on January 7-9, 2013. Ms. ...

Maine Manufacturing, LLC Announces the Acquisition of Laboratory Product Lines from GE Healthcare

SANFORD, Maine, Jan. 3, 2013 /PRNewswire/ -- Maine Manufacturing, LLC announced today that it has acquired from GE Healthcare a line of laboratory products to add to its growing life science portfolio.  The product lines include the market-leading microbiological monitors in both 47mm and 56mm sizes, and the associated broad range of ready-to-use liquid growth media.&#...

Icon's Melphalan Intraocular Injection Granted U.S. Orphan Drug Designation For The Treatment Of Retinoblastoma

SUNNYVALE, Calif., Jan. 3, 2013 /PRNewswire/ -- Icon Bioscience, Inc., (IBI), a privately held biopharmaceutical company that specializes in the development and commercialization of novel ophthalmic pharmaceuticals, today announced that melphalan intraocular injection, the company's investigational product for the treatment of retinoblastoma, has been granted Orphan Drug Designation by...

Quick Search
Advertisement
 

review and buy Biological Therapy market research data and corporate reports here